voclosporin   Click here for help

GtoPdb Ligand ID: 11388

Synonyms: 1,11-anhydro[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl- N-methyl-L-valyl-[(2S,3R,4R,6E)-3-hydroxy-4-methyl- 2-(methylamino)nona-6,8-dienoyl][(2S)-2-aminobutanoyl]- N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine] | E-ISA247 | ISA(TX)247 | ISA-247 | ISA247 | ISATX247 | Lupkynis® | R 1524 | R-1524 | R1524
Approved drug Immunopharmacology Ligand
voclosporin is an approved drug (FDA (2021))
Comment: Voclosporin (ISA247, ISATX247) is a cyclic peptide that is a semi-synthetic cyclosporine analogue [1-3,6], but with distinct clinical efficacy and safety profiles [5]. Like cyclosporine, it has immunosuppressive action, and it binds cyclophilin A [4]. Functionally, it acts as a calcineurin inhibitor. Prior to voclosporin, clinically used calcineurin inhibitors were cyclosporine (cyclosporin A), tacrolimus, and pimecrolimus.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Click here for help
Canonical SMILES C=C/C=C/C[C@H]([C@H]([C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)O)C
Isomeric SMILES C=C/C=C/C[C@H]([C@H]([C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)O)C
InChI InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Voclosporin was advanced to clinical evaluation for autoimmune diseases and the prevention of organ graft rejection. The FDA approved voclosporin (Lupkynis®) in January 2021, as an adjunctive treatment for active lupus nephritis, to be used in combination with a background immunosuppressive therapy. In the EU voclosporin was granted orphan designation (December 2012) as a treatment for non-infectious uveitis.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Calcineurin is a phosphatase that is a key component of immune signalling and which regulates the action of cytotoxic lymphocytes. Drugs that (indirectly) inhibit calcineurin block T cell proliferation and thereby generate their immunosuppressive action.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00244842 Randomized Placebo-Controlled Study of ISA247 in Plaque Psoriasis Phase 3 Interventional Aurinia Pharmaceuticals Inc.
NCT03597464 Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin Phase 3 Interventional Aurinia Pharmaceuticals Inc.
NCT03021499 Aurinia Renal Response in Active Lupus With Voclosporin Phase 3 Interventional Aurinia Pharmaceuticals Inc.